Rob Davidson is the CEO at CURE Pharmaceutical, pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
Topics Discussed:
- Psychedelics acceptance in the U.S. and current state of research
- Micro-dosing psychedelics to treat PTSD, Addiction, mental illness, etc.
- Overview of Oral Thin Film (OTF) Technology
- CURE’s Schedule 1 DEA License and FDA-registered facility
